37,663 Shares in Novo Nordisk A/S (NVO) Acquired by Wedbush Securities Inc.
Wedbush Securities Inc. purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 37,663 shares of the company’s stock, valued at approximately $1,615,000.
A number of other institutional investors have also recently modified their holdings of NVO. Proficio Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after buying an additional 1,505 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after buying an additional 1,918 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after buying an additional 1,553 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $127,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Novo Nordisk A/S by 3,609.0% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,709 shares of the company’s stock worth $127,000 after buying an additional 3,609 shares in the last quarter. Institutional investors own 6.40% of the company’s stock.
Novo Nordisk A/S (NYSE:NVO) opened at 45.81 on Friday. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $47.98. The firm has a 50-day moving average of $42.76 and a 200-day moving average of $38.81. The company has a market capitalization of $113.62 billion, a P/E ratio of 18.74 and a beta of 0.63.
The company also recently declared an annual dividend, which will be paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st will be issued a dividend of $0.336 per share. This represents a yield of 1.07%. The ex-dividend date is Friday, August 18th. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. Novo Nordisk A/S’s payout ratio is 36.00%.
TRADEMARK VIOLATION NOTICE: “37,663 Shares in Novo Nordisk A/S (NVO) Acquired by Wedbush Securities Inc.” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/12/37663-shares-in-novo-nordisk-as-nvo-acquired-by-wedbush-securities-inc.html.
NVO has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. BidaskClub downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Finally, TheStreet upgraded shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company’s stock. Novo Nordisk A/S presently has an average rating of “Hold” and an average target price of $53.00.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.